- Lantheus Reports First Quarter 2024 Financial Results
- Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
- Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
- Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
- Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
- Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
- Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
- Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
- Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
- Lantheus Announces CEO Succession Plan
More ▼
Key statistics
As of last trade, Lantheus Holdings Inc (0L8:STU) traded at 68.74, 47.51% above the 52 week low of 46.60 set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 68.74 |
---|---|
High | 68.74 |
Low | 68.74 |
Bid | 69.84 |
Offer | 71.02 |
Previous close | 69.18 |
Average volume | 364.67 |
---|---|
Shares outstanding | 69.31m |
Free float | 67.55m |
P/E (TTM) | 11.58 |
Market cap | 5.26bn USD |
EPS (TTM) | 6.55 USD |
Data delayed at least 15 minutes, as of May 09 2024.
More ▼